RESEARCH-USE BIOSIMILAR ANTIBODY
Lirilumab
Monoclonal antibody · IgG4
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
TARGETKIRD2
YMonoclonal antibody
CATALOGSC-BS-425
CATALOG NUMBERSC-BS-425
MOLECULAR WEIGHTApprox. 145.52 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
Lirilumab is a recombinant research-use antibody directed against KIRD2.